BioSante Pharmaceuticals to Present at the Bio Investor Forum
LINCOLNSHIRE, Illinois (September 30, 2010) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Bio Investor Forum to be held on October 5-6, 2010 at the Palace Hotel in San Francisco, California.
Stephen M. Simes, BioSante’s president & chief executive officer, will speak on October 5 at 4:30 pm local time. Mr. Simes will provide a status update on BioSante’s lead program, LibiGel® (testosterone gel), in Phase III clinical studies for the treatment of female sexual dysfunction, as well as a general overview of BioSante.
About the Bio Investor Forum
The Bio Investor Forum, sponsored by the Biotechnology Industry Organization (BIO), is a national investor forum to explore investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies. The forum is attended by public and private equity investors, research analysts, investment bankers and industry executives focused on investment and business development opportunities in the life sciences. BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. BIO also produces the annual BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading innovator and partnering meetings held around the world.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials.
Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
For more information please contact:
Harris D. McKinney, Inc.
The Trout Group LLC
For information about participating in the LibiGel clinical studies call or visit the following: